Bypassing fluidics in proteomic screening

Information

  • Research Project
  • 6850644
  • ApplicationId
    6850644
  • Core Project Number
    R43GM070193
  • Full Project Number
    5R43GM070193-02
  • Serial Number
    70193
  • FOA Number
    PA-02-25
  • Sub Project Id
  • Project Start Date
    2/10/2004 - 21 years ago
  • Project End Date
    5/31/2007 - 17 years ago
  • Program Officer Name
    SWAIN, AMY L
  • Budget Start Date
    6/1/2005 - 19 years ago
  • Budget End Date
    5/31/2007 - 17 years ago
  • Fiscal Year
    2005
  • Support Year
    2
  • Suffix
  • Award Notice Date
    6/2/2005 - 19 years ago

Bypassing fluidics in proteomic screening

DESCRIPTION (provided by applicant): The goal of this proposal is to develop a new, groundbreaking technology for the rapid identification of ligands for proteins. Every year, the pharmaceuticals industry loses about $3 billion by targeting genes/proteins wrongfully identified as the cause of disease. In the past decade, thousands of new genes/proteins with a potential role in disease have been identified. Simultaneously, millions of small molecule ligands have been generated in pharmaceutical libraries with little knowledge on their binding potential to these novel gene/protein targets. Potentia has developed a technology that will pave the way towards the matching of these ligands with new potential drug targets. Intelligent access to these libraries of ligands will generate a wealth of knowledge on disease mechanisms that is deemed to revolutionize the process of gene/protein validation in the drug industry. Potentia's technology is unique in its capacity to circumvent the inherent 'slowness' of analyzing molecules in solution. Proteins are immobilized on the tip of an atomic force microscope and then exposed to arrays of biosensors. Each biosensor is individually functionalized with a different small molecule ligand, resulting in Potentia's groundbreaking screening platform. The first aim of this proposal will be to eliminate background noise when functionalizing specialized biosensors with ligands in order to generate sensors for protein binding. The second aim will be to show that an atomic force microscope tip can be used as a bias electrode to gate our specialized biosensors. The third aim will be to determine whether it is possible to retrieve quantitative information from a binding event when using an atomic force microscope tip as a 'robotic arm' to bring a protein in contact with a ligand-coated biosensor. The success of this proposal will generate intelligence on millions of small molecule-protein interactions, generating unprecedented insight in the various gene/protein pathways and their role in disease.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    252000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:252000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    POTENTIA PHARMACEUTICALS, INC
  • Organization Department
  • Organization DUNS
    144375263
  • Organization City
    LOUISVILLE
  • Organization State
    KY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    40202
  • Organization District
    UNITED STATES